Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
NASH Treatment in 2022: review of current and future therapies for non-alcoholic steatohepatitis
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
The slide above illustrates the role of PPARα, PPARβ/δ and PPARγ as key regulators of lipid metabolism, inflammation and glucose There are many compounds in development for the management of NASH. It is very important to understand the path to The diagnosis of NASH is critically important for clinical trials and clinical practice. Today, the gold standard to diagnose NASH Discover all about NASH, NAFLD PPAR agonists ⟶
PPAR’S AS CRITICAL REGULATORS OF METABOLISM
PHASE 3 DEVELOPMENT
IMAGING BIOMARKERS IN NAFLD: COULD THEY AVOID LIVER BIOPSY?
Fibrosis-4 index reflects right ventricular function and prognosis in HFpEF
The authors investigated the prognostic implication of the FIB-4 index regarding right ventricular dysfunction in patients with HFpEF.
NAFL: FIB-4, a strong predictor of both all-cause mortality and liver-related adverse outcomes
The authors analysed data on 30 million patients categorised into three diagnostic groups: NAFLD, NASH, and at risk of NASH.
From NAFLD to MAFLD in terms of nurse perspective
An international consensus panel has produced an influential report renaming the disease from NAFLD to MAFLD and suggesting how the disease should be diagnosed.
MAFLD: a milestone in the history of fatty liver disease
Our growing understanding of the natural history and pathogenesis of MAFLD and the predominant role of metabolic dysfunction in this disease have evoked efforts to redefine fatty liver disease.
New this week!
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital…
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed
NASH Treatment in 2022: review of current and future therapies for non-alcoholic steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a focus on the pathogenesis of NASH and the different pathways
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease, NAFLD.
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including
Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)
This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G
GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to
UPCOMING NASH EVENTS
AASLD THE LIVER MEETING
COMMENTED ARTICLES
Why are we linking PPAR agonists and lipids ?
Prof Sacks, Harvard Medical School, discusses the link between PPAR agonists and plasma lipid risk factors for cardiovascular disease. He explains how free fatty acids go to the
Weight-loss alone may not be sufficient to reverse advanced fibrosis
CATEGORIES
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Latest articles from PubMed
- Non-Alcoholic Fatty Liver Disease Without Metabolic Associated Fatty Liver Disease and the Risk of Metabolic Syndrome
- N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD
- Risk Predictors of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
- Reduced Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease May Be Associated with Depression and Fatigue
- Polysaccharide from <em>Salviae miltiorrhizae</em> Radix et Rhizoma Attenuates the Progress of Obesity-Induced Non-Alcoholic Fatty Liver Disease through Modulating Intestinal Microbiota-Related Gut-Liver Axis
- Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
- Healthy Lifestyle Is Associated with Reduced Mortality in Patients with Non-Alcoholic Fatty Liver Disease
- Clinical Usefulness of Non-Invasive Metabolic-Associated Fatty Liver Disease Risk Assessment Methods in Patients with Full-Blown Polycystic Ovary Syndrome in Relation to the MRI Examination with the Ideal IQ Sequence
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES